DURHAM, N.C. & CAMBRIDGE, Mass. & SEOUL, South Korea, March 10, 2025--Hudson Therapeutics, the U.S. subsidiary of Shaperon, ...
Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Pliant Therapeutics discontinues Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis due to safety concerns, but ...
Two Eradivir employees conduct research on the company's EV25 influenza therapeutic. Eradivir, a clinical stage biotech ...
Clinical Trials Arena on MSN4d
Beckley Psytech completes subjects’ enrolment for Phase IIb trial of TRD therapyBeckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...
Pliant Therapeutics shares were halted in early morning trading after falling 25% to $2.57, after the company said it is discontinuing a phase 2b trial for bexotegrast in patients with idiopathic ...
“The initiation of our Phase 2b isomyosamine trial marks an important milestone in our mission to develop a novel science for immuno-metabolic regulation and increased longevity,” said ...
GOTHENBURG, SE / ACCESS Newswire / March 5, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA)(Nasdaq Stockholm:IRLAB A), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback